LexBlog IP

MAY 10, 2022

Founders Legal retained foreign counsel Foundin IP , has reported that the Beijing Intellectual Property Court issued a ruling in Chugai Pharmaceutical Co., Wenzhou Haihe Pharmaceutical Co., According to the complaint, CHUGAI Pharmaceutical Co., China’s Patent Linkage System.

Intellectual Property 52

Intellectual Property Patent Marketing Marketing 52

IP Tech Blog

AUGUST 18, 2023

During this period, the Chinese National Medical Products Administration (NMPA) may still review but will not approve other generic drug applications (except for co-challengers). The First Patent Linkage Litigation in China On August 5, 2022, China’s Supreme People’s Court issued the landmark decision in Chugai Pharmaceutical Co.,

Litigation 98

Litigation Patent Intellectual Property Branding 98

LexBlog IP

AUGUST 18, 2023

During this period, the Chinese National Medical Products Administration (NMPA) may still review but will not approve other generic drug applications (except for co-challengers). The First Patent Linkage Litigation in China On August 5, 2022, China’s Supreme People’s Court issued the landmark decision in Chugai Pharmaceutical Co.,

Litigation 52

Litigation Patent Intellectual Property Branding 52

Fish & Richardson Trademark & Copyright Thoughts

FEBRUARY 7, 2022

Reynolds Vapor Company v. Regeneron Pharmaceuticals, Inc., and Nippon Shinyaku Co., The most challenged patents relate to aflibercept, held by Regeneron and sold under the trade names Eylea® and Zaltrap®, and tocilizumab, held by Chugai Pharmaceutical Co. In Mylan Laboratories Ltd. Hewlett-Packard Co.,

Reporting 52

Reporting Art Invention Patent 52

Fish & Richardson Trademark & Copyright Thoughts

JANUARY 11, 2022

Several other companies have also announced plans to pursue interchangeable status for biosimilar products. Consistent with this, as shown below in Table 2, numerous companies have publicly announced the submission and/or acceptance of new biosimilar BLAs. Stimufend ® (Fresenius Kabi). Neulasta ® (Amgen). pegfilgrastim.

Litigation 52

Litigation Settlement Patent Marketing 52